May 18, 2026
Sagicor Select Funds Limited Manufacturing & Distribution (SELECTMD)
Unaudited financials for the three months ended March 31, 2026:
Sagicor Select Funds Limited Manufacturing & Distribution (SELECTMD) for the three months ended March 31, 2026, reported an 8% increase in Interest Income totaling $4.54 million compared to $4.20 million in the corresponding period last year.
Dividend income amounted to $35.62 million (2025: $43.25 million), which represents a decrease of 18% year over year. Net changes in fair value on financial assets at fair value through profit or loss amounted to a gain of $118.65 million (2025: loss of $21.45 million). Consequently, total income increased by 511% to $158.82 million compared to $26.00 million for the three months ending March 31, 2025.
Total expenses for the three months ended March 31, 2026, increased 1% to $7.41 million (2025: $7.31 million). Net profit for the three months amounted to $151.41 million, a 710% increase from the $18.69 million reported in 2025.
Consequently, Earnings Per Share for the three months amounted to $0.04 (2025: EPS: $0.00). The twelve-month trailing EPS was $0.04, and the number of shares used in these calculations was 3,816,612,000.
Notably, SELECTMD’s stock price closed the trading period on May 15, 2026, at a price of $0.96 with a corresponding P/E ratio of 27.27x.
Balance Sheet Highlights
The company’s assets totalled $5.00 billion (2025: $4.87 billion). The growth in total assets was primarily driven by a 50% year-over-year increase in “Cash and Cash Equivalents,” which reached $419.13 million (2025: $278.77 million).
Shareholder’s equity was $4.98 billion (2025: $4.85 billion), representing a book value per share of $1.30 (2025: $1.27).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may affect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
